229 related articles for article (PubMed ID: 24817598)
21. Blinded sample size re-estimation in crossover bioequivalence trials.
Golkowski D; Friede T; Kieser M
Pharm Stat; 2014; 13(3):157-62. PubMed ID: 24715672
[TBL] [Abstract][Full Text] [Related]
22. A two stage conditional power adaptive design adjusting for treatment by covariate interaction.
Ayanlowo AO; Redden DT
Contemp Clin Trials; 2008 May; 29(3):428-38. PubMed ID: 18053774
[TBL] [Abstract][Full Text] [Related]
23. A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect.
Ye T; Yu M
Biometrics; 2018 Dec; 74(4):1292-1300. PubMed ID: 29992543
[TBL] [Abstract][Full Text] [Related]
24. Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence.
Maurer W; Jones B; Chen Y
Stat Med; 2018 May; 37(10):1587-1607. PubMed ID: 29462835
[TBL] [Abstract][Full Text] [Related]
25. Sample size calculation for the Andersen-Gill model comparing rates of recurrent events.
Tang Y; Fitzpatrick R
Stat Med; 2019 Oct; 38(24):4819-4827. PubMed ID: 31397911
[TBL] [Abstract][Full Text] [Related]
26. On sample size of the kruskal-wallis test with application to a mouse peritoneal cavity study.
Fan C; Zhang D; Zhang CH
Biometrics; 2011 Mar; 67(1):213-24. PubMed ID: 20345499
[TBL] [Abstract][Full Text] [Related]
27. Sample size reassessment in non-inferiority trials. Internal pilot study designs with ANCOVA.
Friede T; Kieser M
Methods Inf Med; 2011; 50(3):237-43. PubMed ID: 20213039
[TBL] [Abstract][Full Text] [Related]
28. Stopping boundaries adjusted for sample size reestimation and negative stop.
Shun Z
J Biopharm Stat; 2002 Nov; 12(4):485-502. PubMed ID: 12477071
[TBL] [Abstract][Full Text] [Related]
29. A general approach for sample size and statistical power calculations assessing of interventions using a mixture model in the presence of detection limits.
Nie L; Chu H; Cole SR
Contemp Clin Trials; 2006 Oct; 27(5):483-91. PubMed ID: 16769254
[TBL] [Abstract][Full Text] [Related]
30. Simulating recurrent event data with hazard functions defined on a total time scale.
Jahn-Eimermacher A; Ingel K; Ozga AK; Preussler S; Binder H
BMC Med Res Methodol; 2015 Mar; 15():16. PubMed ID: 25886022
[TBL] [Abstract][Full Text] [Related]
31. An internal pilot design for prospective cancer screening trials with unknown disease prevalence.
Brinton JT; Ringham BM; Glueck DH
Trials; 2015 Oct; 16():458. PubMed ID: 26463684
[TBL] [Abstract][Full Text] [Related]
32. Blinded sample size reestimation for negative binomial regression with baseline adjustment.
Zapf A; Asendorf T; Anten C; Mütze T; Friede T
Stat Med; 2020 Jun; 39(14):1980-1998. PubMed ID: 32207171
[TBL] [Abstract][Full Text] [Related]
33. Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis.
Friede T; Kieser M
Pharm Stat; 2011; 10(1):8-13. PubMed ID: 19943322
[TBL] [Abstract][Full Text] [Related]
34. Blinded and unblinded sample size reestimation in crossover trials balanced for period.
Grayling MJ; Mander AP; Wason JMS
Biom J; 2018 Sep; 60(5):917-933. PubMed ID: 30073679
[TBL] [Abstract][Full Text] [Related]
35. Sample size calculations for clinical studies allowing for uncertainty about the variance.
Julious SA; Owen RJ
Pharm Stat; 2006; 5(1):29-37. PubMed ID: 17080926
[TBL] [Abstract][Full Text] [Related]
36. Group sequential designs with robust semiparametric recurrent event models.
Mütze T; Glimm E; Schmidli H; Friede T
Stat Methods Med Res; 2019 Aug; 28(8):2385-2403. PubMed ID: 29890892
[TBL] [Abstract][Full Text] [Related]
37. Sample size re-estimation in group-sequential response-adaptive clinical trials.
Morgan CC
Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
[TBL] [Abstract][Full Text] [Related]
38. Blinded sample size re-estimation in superiority and noninferiority trials: bias versus variance in variance estimation.
Friede T; Kieser M
Pharm Stat; 2013; 12(3):141-6. PubMed ID: 23509095
[TBL] [Abstract][Full Text] [Related]
39. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
40. Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter.
Waleed M; He J; Phadnis MA
J Biopharm Stat; 2024 Jul; 34(4):469-487. PubMed ID: 37545144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
